Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Randomized, Placebo-Controlled, Double-Blind Study of the Induction of Clinical Response and Remission by QBECO in Subjects With Moderate to Severe Crohn's Disease

Next Previous
X
Search
Trial Profile

A Phase 1/2 Randomized, Placebo-Controlled, Double-Blind Study of the Induction of Clinical Response and Remission by QBECO in Subjects With Moderate to Severe Crohn's Disease

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs QBECO (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Qu Biologics

    • Most Recent Events

    • 23 Jul 2019 According to a Qu Biologics media release, the company announced that the results from this study were accepted for publication in Frontiers in Medicine journal.
    • 23 Jul 2019 Results published in the Qu Biologics Media Release
    • 03 May 2017 According to a Qu Biologics media release, data from this trial will be presented at Digestive Disease Week (DDW).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top